Also covered
88/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Starting at $160/mo. Defy Medical is one of the providers covered in our editorial directory that dispenses or coordinates SS-31 (Elamipretide).
Read review →Longevity · Mitochondrial Protective
SS-31 (Elamipretide)
Released: Last reviewed:
SS-31 (also called Elamipretide or Bendavia) is a mitochondria-targeting tetrapeptide that stabilizes cardiolipin and supports electron-transport-chain efficiency. In late-stage clinical trials for several mitochondrial diseases.
SS-31 (Elamipretide) at a glance
SS-31 (also called Elamipretide or Bendavia) is a mitochondria-targeting tetrapeptide that stabilizes cardiolipin and supports electron-transport-chain efficiency. In late-stage clinical trials for several mitochondrial diseases. Mechanism: Mitochondrial-targeted tetrapeptide. Typical route: Subcutaneous. FDA status: Investigational. SS-31 has completed Phase 3 trials for primary mitochondrial myopathy (results mixed) and is studied for Barth syndrome, dry AMD, and heart failure. Not FDA-approved.
Drug classMitochondrial-targeted tetrapeptide
Half-life~5 hours
RouteSubcutaneous
Trial dose40 mg daily
FDA statusInvestigational
Available throughLimited compounding
Mechanism of action
SS-31 selectively concentrates in the inner mitochondrial membrane, binding cardiolipin and preserving the integrity of the electron transport chain. This reduces reactive oxygen species production, supports ATP synthesis, and protects against ischemia-reperfusion injury.
Dosing reference
Subcutaneous: 40 mg daily (most common clinical-trial dose). Some longevity protocols use lower doses (5-20 mg) several times per week. Cycle length varies.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
Investigational. SS-31 has completed Phase 3 trials for primary mitochondrial myopathy (results mixed) and is studied for Barth syndrome, dry AMD, and heart failure. Not FDA-approved.
U.S. telehealth providers that work with SS-31 (Elamipretide)
Also covered
85/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Starting at $180/mo. Marek Health is one of the providers covered in our editorial directory that dispenses or coordinates SS-31 (Elamipretide).
Read review →Also covered
68/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Starting at $199/mo. BreezeMeds is one of the providers covered in our editorial directory that dispenses or coordinates SS-31 (Elamipretide).
Read review →Also covered
80/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Starting at $149/mo. Hone Health is one of the providers covered in our editorial directory that dispenses or coordinates SS-31 (Elamipretide).
Read review →Related longevity peptides
Frequently asked questions about SS-31 (Elamipretide)
Is SS-31 the same as Elamipretide?
Yes. SS-31, Elamipretide, and Bendavia are the same molecule. The 'Elamipretide' name is used by Stealth BioTherapeutics in clinical development.
What conditions has SS-31 been trialed for?
Phase 2/3 trials have covered primary mitochondrial myopathy, Barth syndrome, dry age-related macular degeneration, and heart failure with reduced ejection fraction. Results have been mixed across indications.
References
- First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050. PMID: 24117165
- A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020;11(4):909-918. PMID: 32741132
Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.